Compare HAIN & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HAIN | BMEA |
|---|---|---|
| Founded | 1993 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.1M | 90.5M |
| IPO Year | 1996 | 2021 |
| Metric | HAIN | BMEA |
|---|---|---|
| Price | $0.80 | $1.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | $2.64 | ★ $8.71 |
| AVG Volume (30 Days) | ★ 2.3M | 989.2K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,457,769,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.74 | $0.87 |
| 52 Week High | $4.84 | $3.08 |
| Indicator | HAIN | BMEA |
|---|---|---|
| Relative Strength Index (RSI) | 34.38 | 52.41 |
| Support Level | N/A | $1.24 |
| Resistance Level | $1.23 | $1.41 |
| Average True Range (ATR) | 0.09 | 0.10 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 14.22 | 54.72 |
The Hain Celestial Group Inc is a health and wellness company. It makes natural and organic food and personal-care products. The company offers products across various categories such as snacks, baby & kids food, beverages, meal preparation, and personal care through brands like Garden Veggie Snacks, Terra chips, Garden of Eatin snacks, Hartley's Jelly, and Celestial Seasonings teas, among others. It operates under two reportable segments: North America and International. The majority of its revenue is derived from the North America segment, which represents the sale of its products in the United States and Canada. The International segment includes the sale of its products in the United Kingdom and the Western European region.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.